189 related articles for article (PubMed ID: 19199879)
1. Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
Becker RE; Unni LK; Greig NH
Curr Alzheimer Res; 2009 Feb; 6(1):79-81. PubMed ID: 19199879
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of metrifonate.
Jann MW
Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
[TBL] [Abstract][Full Text] [Related]
3. The perils of Alzheimer's drug development.
Schneider LS; Lahiri DK
Curr Alzheimer Res; 2009 Feb; 6(1):77-8. PubMed ID: 19199878
[No Abstract] [Full Text] [Related]
4. Metrifonate: update on a new antidementia agent.
Ringman JM; Cummings JL
J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
[TBL] [Abstract][Full Text] [Related]
5. Evaluating response to metrifonate.
Tariot PN
J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
Blass JP; Cyrus PA; Bieber F; Gulanski B
Alzheimer Dis Assoc Disord; 2000; 14(1):39-45. PubMed ID: 10718203
[TBL] [Abstract][Full Text] [Related]
7. Treatment of moderate to severe Alzheimer's disease: rationale and trial design.
Herrmann N
Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S103-8. PubMed ID: 17469692
[TBL] [Abstract][Full Text] [Related]
8. In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.
Pohanka M; Jun D; Kuca K
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):680-3. PubMed ID: 18825528
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the symposium on safety pharmacology, presented during the 3rd EPHAR meeting, Lyon, 6-9 July 2001. European Pharmacological Societies.
Fundam Clin Pharmacol; 2002 Apr; 16(2):73-156. PubMed ID: 12102033
[No Abstract] [Full Text] [Related]
10. Student pharmacists: don't forget the product labeling.
Minor PD; Cook GE
J Am Pharm Assoc (2003); 2008; 48(6):696, 700. PubMed ID: 19019796
[No Abstract] [Full Text] [Related]
11. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
12. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
13. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
Relkin NR
Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology.
Venkatakrishnan K; Yalkinoglu O; Dong JQ; Benincosa LJ
Clin Pharmacol Ther; 2020 Oct; 108(4):699-702. PubMed ID: 32356569
[TBL] [Abstract][Full Text] [Related]
15. Metrifonate.
Lamb HM; Faulds D
Drugs Aging; 1997 Dec; 11(6):490-6. PubMed ID: 9413706
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
Crismon ML
Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
[TBL] [Abstract][Full Text] [Related]
17. Drug development and Alzheimer disease.
Roses AD; Pangalos MN
Am J Geriatr Psychiatry; 2003; 11(2):123-30. PubMed ID: 12611742
[No Abstract] [Full Text] [Related]
18. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Martinez A; Castro A
Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
[TBL] [Abstract][Full Text] [Related]
19. Effects of acetylcholinesterase inhibitors on the metabolism of amyloid precursor protein in vitro.
Pakaski M; Papp H; Rakonczay Z; Fakla I; Kasa P
Neurobiology (Bp); 2001; 9(1):55-7. PubMed ID: 11558939
[No Abstract] [Full Text] [Related]
20. New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.
Boulebd H; Ismaili L; Martin H; Bonet A; Chioua M; Marco Contelles J; Belfaitah A
Future Med Chem; 2017 May; 9(8):723-729. PubMed ID: 28485637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
